Thr210
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr210  -  PLK1 (human)

Site Information
YDGERKktLCGtPNy   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448139

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 63 , 88 , 91 ) , electrophoretic mobility shift ( 12 , 91 ) , flow cytometry ( 7 , 11 , 20 ) , immunoprecipitation ( 5 , 7 , 8 , 9 , 11 , 12 , 13 , 14 , 20 , 44 , 63 , 90 ) , mass spectrometry ( 4 , 7 , 10 , 13 , 19 , 20 , 22 , 23 , 24 , 26 , 28 , 30 , 31 , 32 , 33 , 34 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 45 , 46 , 47 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 57 , 58 , 59 , 60 , 61 , 62 , 64 , 65 , 66 , 67 , 68 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 85 , 86 , 87 ) , microscopy-colocalization with upstream kinase ( 16 ) , mutation of modification site ( 6 , 7 , 12 , 13 , 14 , 16 , 20 , 29 , 35 , 48 , 84 , 88 , 89 , 90 , 91 , 92 , 93 ) , phospho-antibody ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 11 , 15 , 16 , 17 , 18 , 20 , 35 , 36 , 44 , 56 , 63 , 84 , 88 , 89 , 90 ) , phosphoamino acid analysis ( 91 ) , phosphopeptide mapping ( 88 , 91 ) , western blotting ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 11 , 12 , 13 , 14 , 16 , 17 , 18 , 20 , 29 , 35 , 36 , 44 , 63 , 84 , 88 , 89 , 90 )
Disease tissue studied:
bone cancer ( 5 , 14 , 17 , 20 , 35 , 84 , 89 ) , brain cancer ( 11 ) , glioblastoma multiforme ( 11 ) , glioma ( 11 ) , breast cancer ( 22 , 30 , 63 ) , HER2 positive breast cancer ( 10 ) , luminal A breast cancer ( 10 ) , luminal B breast cancer ( 10 ) , breast cancer, surrounding tissue ( 10 ) , breast cancer, triple negative ( 10 ) , cervical cancer ( 12 , 68 ) , cervical adenocarcinoma ( 12 , 68 ) , colorectal cancer ( 44 ) , colorectal carcinoma ( 44 ) , gastric cancer ( 41 , 42 , 70 , 71 , 73 , 74 ) , gastric carcinoma ( 41 , 42 , 70 , 71 , 73 , 74 ) , leukemia ( 40 , 62 ) , acute myelogenous leukemia ( 40 ) , chronic myelogenous leukemia ( 62 ) , lung cancer ( 1 , 30 , 67 , 72 ) , non-small cell lung cancer ( 1 , 26 , 30 , 67 , 72 ) , non-small cell lung adenocarcinoma ( 1 , 72 ) , non-small cell squamous cell lung carcinoma ( 72 ) , prostate cancer ( 11 ) , melanoma skin cancer ( 11 ) , fibrosarcoma of soft tissue ( 29 ) , vulvar cancer ( 88 )
Relevant cell line - cell type - tissue:
'muscle, smooth' ( 8 , 18 ) , 1-LN (prostate cell) ( 11 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 64 ) , 293 (epithelial) ( 4 , 7 , 12 , 20 , 60 , 66 ) , A375 (melanocyte) ( 11 ) , A549 (pulmonary) ( 1 , 23 ) , breast ( 10 ) , BT-20 (breast cell) ( 30 ) , BT-549 (breast cell) ( 30 ) , Calu 6 (pulmonary) ( 30 ) , COS (fibroblast) ( 88 ) , DF1 (fibroblast) ( 9 ) , DU 145 (prostate cell) ( 11 ) , FT210 (breast cell) ( 92 ) , H2009 (pulmonary) ( 30 ) , H2077 (pulmonary) ( 30 ) , H2887 (pulmonary) ( 30 ) , H322M (pulmonary) ( 30 ) , HCC1359 (pulmonary) ( 30 ) , HCC1937 (breast cell) ( 30 ) , HCC2279 (pulmonary) ( 30 ) , HCC366 (pulmonary) ( 30 ) , HCC4006 (pulmonary) ( 30 ) , HCC78 (pulmonary) ( 30 ) , HCT116 (intestinal) ( 44 , 81 ) , HEK293T (epithelial) [PLK1 (human)] ( 90 ) , HEK293T (epithelial) ( 14 ) , HeLa (cervical) [PLK1 (human)] ( 90 ) , HeLa (cervical) ( 1 , 3 , 4 , 6 , 7 , 13 , 14 , 16 , 19 , 28 , 29 , 35 , 36 , 45 , 48 , 56 , 59 , 61 , 75 , 76 , 77 , 78 , 79 , 80 , 82 , 86 , 88 , 91 , 92 ) , HeLa K (cervical) ( 12 ) , HeLa S3 (cervical) ( 12 , 57 , 68 , 85 ) , HeLa_Meta (cervical) ( 65 ) , HeLa_NOC (cervical) ( 61 ) , HeLa_Pro (cervical) ( 65 ) , HeLa_Telo (cervical) ( 65 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 22 ) , HMLER ('stem, breast cancer') ( 22 ) , HOP62 (pulmonary) ( 30 ) , HT1080 (fibroblast) ( 29 ) , hTERT-RPE1 (epithelial) ( 13 ) , HUES-9 ('stem, embryonic') ( 58 ) , HUVEC (endothelial) ( 6 ) , Jurkat (T lymphocyte) ( 24 , 31 , 32 , 33 , 34 , 37 , 38 , 39 , 46 , 47 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 83 ) , K562 (erythroid) ( 28 , 62 ) , KATO III (gastric) ( 70 , 74 ) , KG-1 (myeloid) ( 40 ) , MCF-7 (breast cell) ( 30 ) , MDA-MB-231 (breast cell) ( 30 ) , MDA-MB-435S (breast cell) ( 81 ) , MDA-MB-468 (breast cell) ( 30 ) , MEF (fibroblast) ( 63 ) , MKN-45 (gastric) ( 41 , 42 , 71 , 73 , 87 ) , NCI-H1395 (pulmonary) ( 30 ) , NCI-H1568 (pulmonary) ( 30 ) , NCI-H157 (pulmonary) ( 30 ) , NCI-H1648 (pulmonary) ( 30 ) , NCI-H1650 (pulmonary) ( 67 ) , NCI-H1666 (pulmonary) ( 30 ) , NCI-H1703 (squamous) ( 72 ) , NCI-H2030 (pulmonary) ( 30 ) , NCI-H2172 (pulmonary) ( 30 ) , NCI-H3122 (pulmonary) ( 26 ) , NCI-H322 (pulmonary) ( 30 ) , NCI-H647 (pulmonary) ( 30 ) , oocyte ( 88 ) , PtK2 (epithelial) ( 88 ) , SW962 (vulvar) ( 88 ) , U2OS (bone cell) [GR (human)] ( 93 ) , U2OS (bone cell) ( 5 , 14 , 17 , 20 , 35 , 84 , 89 ) , U373 MG (glial) ( 11 ) , Vero (epithelial) ( 9 ) , ZR-75-1 (breast cell) ( 63 )

Upstream Regulation
Regulatory protein:
Abl (human) ( 7 ) , ARPC1B (human) ( 63 ) , BORA (human) ( 5 ) , DNAPK (human) ( 1 ) , MYPT1 (human) ( 88 ) , optineurin (human) ( 36 ) , PLK1 (human) ( 8 , 18 ) , PPP6C (human) ( 1 ) , SLK (human) ( 8 ) , WAC (human) ( 3 )
Putative in vivo kinases:
AurA (human) ( 84 )
Kinases, in vitro:
AurA (human) ( 3 , 84 ) , AurB (human) ( 16 ) , Cot (human) ( 69 ) , LOK (human) ( 91 )
Putative upstream phosphatases:
PPP1CA (human) ( 88 )
Phosphatases, in vitro:
PPP1CA (human) ( 88 )
Treatments:
ACh ( 8 ) , adriamycin ( 90 ) , alpha2-macroglobulin ( 11 ) , BI_4834 ( 45 ) , BX795 ( 11 ) , caffeine ( 17 , 84 ) , doxycycline ( 3 ) , EDTA ( 20 ) , etoposide ( 5 ) , imatinib ( 7 ) , MG132 ( 89 ) , MLN8054 ( 59 , 84 ) , nocodazole ( 1 , 3 , 68 , 85 , 89 , 90 ) , PDGF ( 18 ) , siRNA ( 88 ) , sphingosine_1-phosphate ( 6 ) , TAME ( 1 ) , taxol ( 84 ) , thymidine ( 27 , 85 ) , ZM447439 ( 84 )

Downstream Regulation
Effects of modification on PLK1:
enzymatic activity, induced ( 3 , 5 , 12 , 16 , 89 , 91 , 92 , 93 ) , intracellular localization ( 15 , 17 ) , molecular association, regulation ( 92 ) , phosphorylation ( 3 , 35 )
Effects of modification on biological processes:
cell cycle regulation ( 3 , 29 , 84 , 89 , 91 , 93 ) , cell growth, induced ( 11 , 18 ) , transcription, altered ( 35 )
Inhibit interaction with:
PLK1 (human) ( 92 )

References 

1

Douglas P, et al. (2020) Nocodazole-induced expression and phosphorylation of anillin and other mitotic proteins is decreased in DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-deficient cells and rescued by inhibition of the Anaphase Promoting Complex/Cyclosome (APC/C) with proTAME but not apcin. Mol Cell Biol
32284347   Curated Info

2

Tian L, et al. (2020) PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression. Oncogene
32060423   Curated Info

3

Qi F, et al. (2018) WAC Promotes Polo-like Kinase 1 Activation for Timely Mitotic Entry. Cell Rep 24, 546-556
30021153   Curated Info

4

Gheghiani L, et al. (2017) PLK1 Activation in Late G2 Sets Up Commitment to Mitosis. Cell Rep 19, 2060-2073
28591578   Curated Info

5

Bruinsma W, et al. (2017) Inhibition of Polo-like kinase 1 during the DNA damage response is mediated through loss of Aurora A recruitment by Bora. Oncogene 36, 1840-1848
27721411   Curated Info

6

Andrieu G, et al. (2017) Sphingosine 1-phosphate signaling through its receptor S1P5 promotes chromosome segregation and mitotic progression. Sci Signal 10
28351953   Curated Info

7

Yang X, et al. (2017) Cervical Cancer Growth Is Regulated by a c-ABL-PLK1 Signaling Axis. Cancer Res 77, 1142-1154
27899378   Curated Info

8

Li J, et al. (2016) Polo-like Kinase 1 Regulates Vimentin Phosphorylation at Ser-56 and Contraction in Smooth Muscle. J Biol Chem 291, 23693-23703
27662907   Curated Info

9

Chiu HC, et al. (2016) Suppression of Vimentin Phosphorylation by the Avian Reovirus p17 through Inhibition of CDK1 and Plk1 Impacting the G2/M Phase of the Cell Cycle. PLoS One 11, e0162356
27603133   Curated Info

10

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

11

Gopal U, Gonzalez-Gronow M, Pizzo SV (2016) Activated α2-Macroglobulin Regulates Transcriptional Activation of c-MYC Target Genes through Cell Surface GRP78 Protein. J Biol Chem 291, 10904-15
27002159   Curated Info

12

Thomas Y, et al. (2016) Cdk1 Phosphorylates SPAT-1/Bora to Promote Plk1 Activation in C. elegans and Human Cells. Cell Rep 15, 510-8
27068477   Curated Info

13

Lasek AL, McPherson BM, Trueman NG, Burkard ME (2016) The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation. PLoS One 11, e0150225
26919439   Curated Info

14

Meng L, et al. (2015) Bimodal Interaction of Mammalian Polo-Like Kinase 1 and a Centrosomal Scaffold, Cep192, in the Regulation of Bipolar Spindle Formation. Mol Cell Biol 35, 2626-40
26012549   Curated Info

15

Miyamoto T, et al. (2015) The Microtubule-Depolymerizing Activity of a Mitotic Kinesin Protein KIF2A Drives Primary Cilia Disassembly Coupled with Cell Proliferation. Cell Rep
25660017   Curated Info

16

Shao H, et al. (2015) Spatiotemporal dynamics of Aurora B-PLK1-MCAK signaling axis orchestrates kinetochore bi-orientation and faithful chromosome segregation. Sci Rep 5, 12204
26206521   Curated Info

17

Bruinsma W, et al. (2015) Spatial Separation of Plk1 Phosphorylation and Activity. Front Oncol 5, 132
26114094   Curated Info

18

Jiang S, Tang DD (2015) Plk1 regulates MEK1/2 and proliferation in airway smooth muscle cells. Respir Res 16, 93
26242183   Curated Info

19

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

20

Banerjee S, et al. (2014) Interplay between Polo kinase, LKB1-activated NUAK1 kinase, PP1βMYPT1 phosphatase complex and the SCFβTrCP E3 ubiquitin ligase. Biochem J 461, 233-45
24785407   Curated Info

21

Douglas P, et al. (2014) Polo-like kinase 1 (PLK1) and protein phosphatase 6 (PP6) regulate DNA-dependent protein kinase catalytic subunit (DNA-PKcs) phosphorylation in mitosis. Biosci Rep 34
24844881   Curated Info

22

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

23

Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9
23836654   Curated Info

24

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

25

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

26

Rikova K (2013) CST Curation Set: 18459; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

27

Lee YC, et al. (2013) Glycogen synthase kinase 3 β activity is required for hBora/Aurora A-mediated mitotic entry. Cell Cycle 12, 953-60
23442801   Curated Info

28

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

29

Ando K, Ozaki T, Hirota T, Nakagawara A (2013) NFBD1/MDC1 Is Phosphorylated by PLK1 and Controls G2/M Transition through the Regulation of a TOPOIIα-Mediated Decatenation Checkpoint. PLoS One 8, e82744
24349352   Curated Info

30

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

31

Mulhern D (2012) CST Curation Set: 13827; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

32

Mulhern D (2012) CST Curation Set: 13828; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

33

Mulhern D (2012) CST Curation Set: 13829; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

34

Mulhern D (2012) CST Curation Set: 13830; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

35

Fairley JA, et al. (2012) Direct Regulation of tRNA and 5S rRNA Gene Transcription by Polo-like Kinase 1. Mol Cell 45, 541-52
22281053   Curated Info

36

Kachaner D, et al. (2012) Plk1-dependent phosphorylation of optineurin provides a negative feedback mechanism for mitotic progression. Mol Cell 45, 553-66
22365832   Curated Info

37

Mulhern D (2012) CST Curation Set: 13107; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

38

Mulhern D (2012) CST Curation Set: 13108; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

39

Mulhern D (2012) CST Curation Set: 13109; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

40

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

41

Mulhern D (2012) CST Curation Set: 13402; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

42

Mulhern D (2012) CST Curation Set: 13405; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

43

Rikova K (2011) CST Curation Set: 13126; Year: 2011; Biosample/Treatment: cell line, MGH-4/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

44

Mielgo A, et al. (2011) A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med 17, 1641-5
22081024   Curated Info

45

Grosstessner-Hain K, et al. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome. Mol Cell Proteomics 10, M111.008540
21857030   Curated Info

46

Mulhern D (2011) CST Curation Set: 12677; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

47

Guo A (2011) CST Curation Set: 12074; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

48

Kang YH, et al. (2011) Mammalian polo-like kinase 1-dependent regulation of the PBIP1-CENP-Q complex at kinetochores. J Biol Chem 286, 19744-57
21454580   Curated Info

49

Guo A (2011) CST Curation Set: 11884; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

50

Guo A (2011) CST Curation Set: 11885; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

51

Guo A (2011) CST Curation Set: 11887; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

52

Guo A (2011) CST Curation Set: 11890; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

53

Guo A (2011) CST Curation Set: 11891; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

54

Guo A (2011) CST Curation Set: 11892; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

55

Guo A (2011) CST Curation Set: 11893; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

56

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Menendez JA (2011) Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus. Cell Cycle 10, 1295-302
21474997   Curated Info

57

Santamaria A, et al. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle. Mol Cell Proteomics 10, M110.004457
20860994   Curated Info

58

Rigbolt KT, et al. (2011) System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal 4, rs3
21406692   Curated Info

59

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

60

Goswami T, Ballif B. (2011) Methods for the Isolation of Phosphoproteins and Phosphopeptides for Mass Spectrometry Analysis: Toward Increased Functional Phosphoproteomics
Curated Info

61

Hegemann B, et al. (2011) Systematic phosphorylation analysis of human mitotic protein complexes. Sci Signal 4, rs12
22067460   Curated Info

62

Beausoleil S (2010) CST Curation Set: 10282; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

63

Molli PR, et al. (2010) Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol 190, 101-14
20603326   Curated Info

64

Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53
20363803   Curated Info

65

Dulla K, et al. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression. Mol Cell Proteomics 9, 1167-81
20097925   Curated Info

66

Guo A (2010) CST Curation Set: 6270; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST]
Curated Info

67

Possemato A (2010) CST Curation Set: 9749; Year: 2010; Biosample/Treatment: cell line, H1650/Phenformin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

68

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

69

Wu B, Jiang P, Mu Y, Wilmouth RC (2009) Cancer Osaka thyroid (Cot) phosphorylates Polo-like kinase (PLK1) at Ser137 but not at Thr210. Biol Chem 390, 1271-7
19804365   Curated Info

70

Possemato A (2009) CST Curation Set: 8414; Year: 2009; Biosample/Treatment: cell line, KATO III/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

71

Possemato A (2009) CST Curation Set: 8412; Year: 2009; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

72

Possemato A (2009) CST Curation Set: 8410; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

73

Possemato A (2009) CST Curation Set: 8411; Year: 2009; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

74

Possemato A (2009) CST Curation Set: 8413; Year: 2009; Biosample/Treatment: cell line, KATO III/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

75

Zhou J (2009) CST Curation Set: 7590; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

76

Zhou J (2009) CST Curation Set: 7593; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

77

Zhou J (2009) CST Curation Set: 7592; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

78

Zhou J (2009) CST Curation Set: 7594; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

79

Zhou J (2009) CST Curation Set: 7591; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

80

Zhou J (2009) CST Curation Set: 7589; Year: 2009; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

81

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

82

Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8
19276368   Curated Info

83

Farnsworth C (2009) CST Curation Set: 6186; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) PKC Substrate Antibody Cat#: 2261, PTMScan(R) Phospho-PKC Substrate Motif (K/RXpSXK/R) Immunoaffinity Beads Cat#: 1985
Curated Info

84

Macůrek L, et al. (2008) Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 455, 119-23
18615013   Curated Info

85

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

86

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

87

Rush J (2008) CST Curation Set: 4496; Year: 2008; Biosample/Treatment: cell line, MKN-45/untreated &'||' normal; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

88

Yamashiro S, et al. (2008) Myosin phosphatase-targeting subunit 1 regulates mitosis by antagonizing polo-like kinase 1. Dev Cell 14, 787-97
18477460   Curated Info

89

van de Weerdt BC, et al. (2005) Uncoupling anaphase-promoting complex/cyclosome activity from spindle assembly checkpoint control by deregulating polo-like kinase 1. Mol Cell Biol 25, 2031-44
15713655   Curated Info

90

Tsvetkov L, Stern DF (2005) Phosphorylation of Plk1 at S137 and T210 is inhibited in response to DNA damage. Cell Cycle 4, 166-71
15611664   Curated Info

91

Jang YJ, Ma S, Terada Y, Erikson RL (2002) Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase. J Biol Chem 277, 44115-20
12207013   Curated Info

92

Jang YJ, Lin CY, Ma S, Erikson RL (2002) Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc Natl Acad Sci U S A 99, 1984-9
11854496   Curated Info

93

Smits VA, et al. (2000) Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2, 672-6
10980711   Curated Info